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S U M M A R Y
Background: Studies that have assessed NRAMP1 polymorphisms and their association with susceptibil-
ity to tuberculosis (TB) in humans have yielded conﬂicting results. In this study, we evaluated the
association between NRAMP1 gene polymorphisms and the risk of the development of active TB in
Tunisian populations.
Methods: The distribution of 30-UTR and D543N polymorphisms in 223 TB patients (168 patients with
pulmonary TB (PTB) and 55 patients with extrapulmonary TB (EPTB)) and 150 healthy donors was
determined by PCR-restriction fragment length polymorphism (RFLP) method.
Results: We found that AA and AG genotypes appeared to be associated with susceptibility to PTB (odds
ratio (OR) 10.8, 95% conﬁdence interval (CI) 1.37–230.8; p corrected for the number of genotypes
(pc) = 0.018) and EPTB (OR 4.37, 95% CI 1.64–11.82; pc = 0.0024), respectively, in patients aged less than
30 years. However, wild-type GG genotype appeared to be associated with resistance against PTB in
females (OR 0.1, 95% CI 0.01–0.74; pc = 0.03). The 30-UTR del/del genotype appeared to be associated
with susceptibility to PTB in patients aged less than 30 years (OR 3.75, 95% CI 1.5–9.52; pc = 0.003). In
contrast, TGTG+/del might be associated with resistance against the development of active PTB (OR 0.23,
95% CI 0.08–0.65; pc = 0.003). A-del haplotype appeared to be associated with susceptibility to PTB (OR
1.79, 95% CI 1.11–2.9; pc = 0.04).
Conclusions: Collectively, our results suggest an association of NRAMP1 30-UTR and D543N
polymorphisms with susceptibility to mycobacterial infection in Tunisian populations in relation to
age and sex.
Crown Copyright  2012 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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Tuberculosis (TB) is a major cause of morbidity and mortality
worldwide, especially in Southeast Asian, African, and Western
Paciﬁc regions. Globally, an estimated 8.9–9.9 million new cases and
1.3 million deaths among HIV-negative individuals were reported in
2009.1 In addition, it has been estimated that only 10% of HIV-
negative individuals infected with Mycobacterium tuberculosis will
develop clinical disease in their lifetime. A minority of individuals
have a higher susceptibility to TB, most likely resulting from
interplay between multiple host and environmental factors.2–4
Some genetic variations, such as Mendelian-inherited mutations in
the genes encoding interferon gamma (IFN-g) receptor, interleukin-
12, and signal transducers, are rare and are associated with severe
mycobacterial infection.5–8 We have recently reported that IFN-g
polymorphism is associated with an increased risk of the* Corresponding author. Tel.: +216 73219504; fax: +216 73219504.
E-mail address: wbenselma@hotmail.com (W. Ben-Selma).
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http://dx.doi.org/10.1016/j.ijid.2011.11.016development of active TB in Tunisian patients.9 Other genetic
variations, such as polymorphism of genes encoding human
leukocyte antigen (HLA) type,10,11 vitamin D receptor (VDR),12
dendritic cell-speciﬁc intracellular adhesion molecule-3-grabbing
nonintegrin (DC-SIGN),13 complement system components C2, C4,
BF, and C3,14 and the solute carrier family 11 member a1 protein
(SLC11A1, formerly known as NRAMP1),4,15,16 are known to be key
factors in the development of TB.
The NRAMP1 gene encodes an ion transporter that localizes to the
lysosomal membrane during the phagocytosis of mycobacteria and
other pathogens, and it might regulate ion or divalent cation
transport.17,18 It is well established that the NRAMP1 gene product
plays a pivotal role in resistance to intracellular pathogens, including
bacillus Calmette–Gue´rin (BCG), Leishmania, Salmonella, and myco-
bacteria.19 Taken together, these data suggest the importance of
NRAMP1 in the human immune response to M. tuberculosis infection.
NRAMP1 has been cloned and mapped to human chromosome
2q35.20,21 Several functional polymorphisms have been described
in the NRAMP1 gene.20,22 In addition, these polymorphisms have
been associated with a number of diseases, including TB,Ltd on behalf of International Society for Infectious Diseases. All rights reserved.
Figure 1. D543N genotyping by PCR-RFLP. GG genotype = lanes 1 and 3; AG
genotype = lane 2; AA genotype = lane 4. M: 50 bp DNA size markers. Numbers on
the left indicate the size of the amplicons.
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sis.23 Four polymorphisms – 30-UTR, D543N, INT4, and 50(GT)n –
have been examined for their association with susceptibility to TB
in different studies, and the data have been summarized in recent
reviews, as well as in a meta-analysis of various studies.16,24–27 In
the meta-analysis, a subgroup analysis of the four separate
polymorphisms indicated that three of them are associated with
susceptibility to TB in Asian populations: 30-UTR, D543N, and
50(GT)n. No signiﬁcant results were obtained when European
studies were grouped. African populations showed signiﬁcance in
all studies, except the 30-UTR.4,15,25,26 Collectively, these data
showed ethnic and geographic differences in human susceptibility
to active TB and NRAMP1 polymorphisms.4–15
Tunisia is a region with moderate TB prevalence (9.5 new cases
per 100 000 population) and incidence (21 cases/100 000/year)
and a predominating M. tuberculosis strain.28 Because the NRAMP1
gene is an important candidate factor for human susceptibility to
active TB and there is no report investigating its impact on active
TB outcomes in Tunisian populations, the present study focused on
the association between NRAMP1 polymorphisms and susceptibil-
ity to active TB in Tunisia. The association between 30-UTR and
D543N NRAMP1 polymorphisms and the risk of developing active
TB (pulmonary and extrapulmonary) was investigated in the
Tunisian population grouped by sex and age.
2. Materials and methods
2.1. Studied populations
2.1.1. Patients with tuberculosis
From January 2009 to September 2010, a total of 168 patients
with active pulmonary TB (PTB) (127 males and 41 females; age
range 14–78 years, mean age 44 years) and 55 patients with
extrapulmonary TB (EPTB) (33 males and 22 females; age range
17–84 years, mean age 42 years), from the Pneumology Unit, CHU
Farhat Hached and the Health Care Service, Sousse, Tunisia were
enrolled in this study. Informed written consent was obtained from
all individuals prior to blood sampling, and this study was
approved by the Ethics Committee of the Farhat Hached University
Hospital. Demographic, clinical, and microbiological data for all
adult subjects were collected on individual data collection forms
and entered into a computer database. None of the patients with
active TB or the controls had a history of severe pathologies,
including HIV infection, cardiovascular diseases, diabetes, asthma,
atopy or autoimmune diseases, and cancer. All patients had been
vaccinated with BCG.
The patients had not yet started anti-tuberculosis treatment
when the blood samples were taken.
Patients with active PTB were diagnosed clinically, including a
chest radiograph, and the diagnosis subsequently conﬁrmed by
conventional bacteriological examination, including microscopic
examination for acid-fast bacilli and culture on Lowenstein–Jensen
medium, in accordance with the statements of the American
Thoracic Society.29
The diagnosis of EPTB cases was based on conventional
bacteriological examination and/or histological features (granulo-
matous formation). The extrapulmonary locations comprised:
stomach (n = 1), genitourinary tract (n = 2), lymph nodes (n = 36),
meninges (n = 2), peritoneum (n = 3), pleura (n = 8), and spleen
(n = 3).
2.1.2. Controls
Blood samples were obtained from healthy control subjects
(135 males and 15 females; age range 24–55 years, mean age 35
years) admitted to the Transfusion Unit, CHU Farhat Hached,
Sousse, Tunisia. None of the control subjects had previouslysuffered from TB and all had negative chest X-rays and negative
sputum culture results for M. tuberculosis.
2.2. DNA extraction
Genomic DNA was prepared from 300 ml of fresh blood
peripheral blood mononuclear cells (PBMCs) using a Wizard
Genomic DNA Puriﬁcation Kit (Promega Corporation, Madison, WI,
USA) in accordance with the manufacturer’s recommendations;
this was then quantiﬁed using a NanoDrop spectrophotometer
(UV-Visible NanoDrop 1000, Thermo Fisher Scientiﬁc Inc.) and
standardized to 50 ng/ml. Aliquots were stored at 20 8C for
further genotyping.
2.3. NRAMP1 genotyping
The following two NRAMP1 polymorphisms were typed: (1) a
nonconservative single-base substitution at codon 543 in exon 15
that changes aspartic acid to asparagine (D543N), and (2) a TGTG
deletion in the 30-untranslated region (30-UTR) located at 55
nucleotides downstream of the last codon in exon 15 (1729
+55del4).30,31
A large number of single-nucleotide polymorphisms (SNPs) have
already been identiﬁed, with more than 21 000 entries in the NCBI
SNP database alone (http://www.ncbi.nlm.nih.gov/snp). The ability
to genotype this abundant source of variation rapidly and accurately
is becoming ever more important in the genetics community.32 A
variety of available technologies have the potential for use in the
high-throughput genotyping laboratory.33 Of these technologies,
polymerase chain reaction and restriction fragment length poly-
morphism (PCR-RFLP), which is relatively simple and economical,
can be applied to a large number of samples.34
PCR-RFLP analysis was used to type polymorphisms of the
NRAMP1 genes, as described in a previous study.30 Brieﬂy, the 30
region of NRAMP1, including two sites of polymorphism (D543N
and 30-UTR), was ampliﬁed using sense primer 50-GCATCTCCC-
CAATTCATGGT-30 and antisense primer 50-AACTGTCCCACTC-
TATCCTG-30. The product size was 240 or 244 bp. PCR
ampliﬁcations were performed in 25-ml reaction volumes contain-
ing 100 ng genomic DNA, 2.0 mmol/l MgCl2, 200 mmol/l of each
deoxynucleotide triphosphate, 10 pmol of each primer, and 1 U Taq
DNA polymerase (Promega, USA). The mixture was then initially
subjected to 95 8C for 5 min, followed by 35 cycles of denaturation
at 95 8C for 1 min, annealing at 56 8C for 1 min, and extension at
72 8C for 1 min; the ﬁnal extension was at 72 8C for 7 min; a
MyCycler thermal cycler (Bio-Rad, USA) was used. To determine
each polymorphism, restriction enzymes were used: AvaII
(G#GWCC) was used for D543N, with allele G (aspartic acid)
showing at three bands of 126 bp, 79 bp, and 39 bp, and allele A
(asparagine) showing at two bands of 201 bp and 39 bp (Figure 1);
FokI (GGATG(9/13)) was used for 30-UTR, with allele TGTG+
showing 211 bp and 33 bp fragments, and allele del showing a
240 bp fragment (Figure 2). The digestion products were separated
by electrophoresis on 4% agarose gels (Sigma, USA) containing
ethidium bromide (0.5 mg/ml) (Sigma, USA) and were visualized
under UV illumination using Gel Doc XR (Bio-Rad, USA).
Figure 2. 30-UTR genotyping by PCR-RFLP. TGTG+/+ genotype = lane 1; TGTG+/del
genotype = lane 2; del/del genotype = lane 3. M: 50 bp DNA size markers. Numbers
on the left indicate the size of the amplicons.
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For genetic association analyses, each polymorphism was
tested for deviations from Hardy–Weinberg equilibrium in
patients and controls.35
The statistical analysis was performed using Epi Info 6.0 software
(Centers for Disease Control and Prevention, Atlanta, GA, USA). The
associations between the allelic/genotype frequencies and the
clinical forms of TB, as well as the odds ratio (OR) for the
susceptibility to infection, were obtained by Chi-square test. A p-
value of <0.05 was considered statistically signiﬁcant. The
Bonferroni correction was applied for multiple tests, and pc < 0.05
was considered to show a statistically signiﬁcant difference.
In the present study, sample sizes were calculated considering a
frequency of the NRAMP1 D543 AA genotype in the general
population of 45.58%, as reported in a previous case–control study
carried out in Africa in 1998.24 Considering a 5% level of
signiﬁcance and a power of 80%, the minimum number of subjects
needed for the study to detect an OR of 2.0 was 148 cases and 148
controls.
Haplotype frequencies were inferred by exact solution from the
Hill equation using the program CubEX (http://www.oege.org/
software/cubex). This program estimates the haplotype frequen-
cies, the normalized linkage disequilibrium (LD) parameter (D0),
and the LD correlation coefﬁcient between two loci (r2).36
3. Results
3.1. Hardy–Weinberg equilibrium
The genotype frequencies of NRAMP1 D543N and 30-UTR
polymorphisms were in Hardy–Weinberg equilibrium in both
the patient and control groups (p > 0.05).Table 1
D543N and 30-UTR allele and genotype frequencies (n (%)) in pulmonary and extrapulm
PTB + EPTB
(n = 223)
Controls
(n = 150)
D543N
Genotype
AA 10 (5) 1 (1) 
AG 70 (31) 34 (23)
GG 143 (64) 115 (76)
Allele
A 90 (20) 36 (12)
G 356 (80) 264 (88)
30-UTR
Genotype
del/del 102 (46) 68 (46)
TGTG+/del 88 (39) 62 (41)
TGTG+/+ 33 (15) 20 (13)
Allele
del 292 (65) 198 (66)
TGTG+ 154 (35) 102 (34)
PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis; OR, odds ratio; CI, c
a pc: Bonferroni correction. As multiple comparisons were made, Bonferroni’s corre
genotypes (three).
b Fisher’s exact test.3.2. Associations of NRAMP1 D543N with TB susceptibility
In this study, genotyping of 30-UTR and D543N NRAMP1
polymorphisms was investigated by two PCR-RFLPs, as reported
previously.30,31 In their study, Roy et al.31 conﬁrmed the results
obtained by PCR-RFLP for the SNPs investigated using direct
sequencing.
The frequencies of the A and G alleles were the variables
investigated in four studied groups: PTB and EPTB together (Table
1), PTB alone (Table 2), EPTB alone (Table 3), and controls.
Compared with healthy controls, the A allele was signiﬁcantly
more frequent in the TB group and seemed to be associated with an
increased risk of the development of these clinical forms (PTB and
EPTB; 20% vs. 12%; OR 1.85, 95% conﬁdence interval (CI) 1.2–2.88,
p = 0.003) (Table 1), and of PTB (21% vs. 12%; OR 1.93, 95% CI 1.22–
3.06; p = 0.002) (Table 2).
The three genotypes AA, AG, and GG were observed in the PTB
and control groups (Figure 1). Even after correcting p-values (pc)
using the Bonferroni method for multiple tests, a signiﬁcant
association was found between the AA genotype and an increased
risk of the development of PTB (OR 9.43, 95% CI 1.22–199.3;
pc = 0.03). However, a low OR value (OR 0.55, 95% CI 0.32–0.92;
pc = 0.03) suggested that the presence of the wild-type GG
genotype might be protective against the development of active
PTB.
When TB patients and healthy individuals were stratiﬁed by
sex, signiﬁcant differences in the distribution of genotypes was
observed in females for wild-type GG genotype in the PTB group
(5% vs. 33%, OR 0.1, 95% CI 0.01–0.74; pc = 0.03). In addition,
patients aged less than 30 years with AA genotype appeared to be
at increased risk of developing PTB (OR 10.8, 95% CI 1.37–230.8;
pc = 0.018) (Table 4), and with AG genotype at increased risk of
developing EPTB (OR 4.37, 95% CI 1.64–11.82; pc = 0.0024) (Table
5). However, patients with GG genotype appeared to be protected
against the development of active EPTB (OR 0.25, 95% CI 0.09–0.65;
pc = 0.003) (Table 5).
3.3. Associations of NRAMP1 30-UTR with TB susceptibility
The del allele frequencies were similar in the different studied
groups – PTB, EPTB, and healthy controls (Tables 2 and 3). There
was no statistically signiﬁcant difference in the frequency
distribution of the three genotypes del/del, TGTG+/del, and
TGTG+/+ in the TB patient and control groups (Tables 1–3).onary tuberculosis cases and in controls
p-Value (pca) OR (95% CI)
0.02b (NS) 7 (0.91–147.61)
 0.06 (NS) 1.56 (0.95–2.58)
 0.01 (0.03) 0.54 (0.33–0.89)
 0.003 1.85 (1.2–2.88)
 0.93 (NS) 1.02 (0.66–1.57)
 0.71 (NS) 0.93 (0.59–1.44)
 0.69 (NS) 1.13 (0.6–2.14)
 0.88 0.98 (0.71–1.35)
onﬁdence interval; NS, not signiﬁcant.
ction was applied to a signiﬁcant p-value that was multiplied by the number of
Table 2
D543N and 30-UTR allele and genotype frequencies (n (%)) in pulmonary tuberculosis cases and in controls by gender
PTB (n=168) Controls (n=150) p-Valuea (pc) ORa (95% CI) p-Valueb (pc) ORb (95% CI) p-Valuec (pc) ORc (95% CI)
M+F (%) M (%) F (%) M+F (%) M (%) F (%)
D543N
Genotype
AA 10 (6) 7 (6) 3 (7) 1 (1) 1 (1) 0 (0) 0.01 (0.03) 9.43 (1.22–199.3) 0.02d (NS) 7.82 (0.95–171.49) 0.38d (NS) ND
AG 50 (30) 14 (11) 36 (88) 34 (23) 24 (18) 10 (67) 0.15 (NS) 1.45 (0.85–2.47) 0.16 (NS) 0.61 (0.28–1.3) 0.07d (NS) 3.6 (0.71–18.75)
GG 108 (64) 106 (83) 2 (5) 115 (76) 110 (81) 5 (33) 0.01 (0.03) 0.55 (0.32–0.92) 0.67 (NS) 1.15 (0.58–2.28) 0.01 (0.03)d 0.1 (0.01–0.74)
Allele
A 70 (21) 28 (11) 42 (51) 36 (12) 26 (10) 10 (33) 0.002 1.93 (1.22–3.06) 0.59 1.16 (0.64–2.12) 0.09 2.1 (0.81–5.53)
G 266 (79) 226 (89) 40 (49) 264 (88) 244 (90) 20 (67)
30-UTR
Genotype
del/del 80 (48) 60 (47) 20 (49) 68 (46) 63 (47) 5 (34) 0.68 (NS) (0.69–1.75) 0.92 (NS) 1.02 (0.61–1.71) 0.3 (NS) 1.9 (0.48–7.86)
TGTG+/del 67 (40) 52 (41) 15 (36) 62 (41) 54 (40) 8 (53) 0.79 (NS) 0.94 (0.59–1.51) 0.87 (NS) 1.04 (0.62–1.76) 0.25 (NS) 0.5 (0.13–1.95)
TGTG+/+ 21 (12) 15 (12) 6 (15) 20 (13) 18 (13) 2 (13) 0.82 (NS) 0.93 (0.46–1.88) 0.71 (NS) 0.87 (0.39–1.92) 0.63d (NS) 1.11 (0.17–9.2)
Allele
del 227 (68) 172 (68) 55 (67) 198 (66) 180 (67) 18 (60) 0.67 1.07 (0.76–1.51) 0.79 1.05 (0.72–1.54) 0.48 1.36 (0.52–3.5)
TGTG+ 109 (32) 82 (32) 27 (33) 102 (34) 90 (33) 12 (40)
PTB, pulmonary tuberculosis; M,male; F, female; OR, odds ratio; CI, conﬁdence interval; NS, not signiﬁcant; ND, not determined; pc, Bonferroni correction (asmultiple comparisons weremade, Bonferroni’s correctionwas applied to
a signiﬁcant p-value that was multiplied by the number of genotypes (three)).
a Male and female cases of pulmonary tuberculosis vs. male and female control cases.
b Male cases of pulmonary tuberculosis vs. male control cases.
c Female cases of pulmonary tuberculosis vs. female control cases.
d Fisher’s exact test.
Table 3
D543N and 30-UTR allele and genotype frequencies (n (%)) in extrapulmonary tuberculosis cases and in controls by gender
EPTB (n=55) Controls (n=150) p-Valuea (pc) ORa (95% CI) p-Valueb (pc) ORb (95% CI) p-Valuec (pc) ORc (95% CI)
M+F (%) M (%) F (%) M+F (%) M (%) F (%)
D543N
Genotype
AA 0 (0) 0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 0.7d (NS) 0 (0–47.94) 0.8d (NS) 0 (0–72.71) ND ND
AG 20 (36) 1 (3) 19 (86) 34 (23) 24 (18) 10 (67) 0.04 (NS) 1.95 (0.95–4.01) 0.02d (NS) 0.14 (0.01–1.07) 0.1 (NS) 3.17 (0.5–21.81)
GG 35 (64) 32 (97) 3 (14) 115 (76) 110 (81) 5 (33) 0.06 (NS) 0.53 (0.26–1.09) 0.02 (NS) 7.27 (0.98–149.64) 0.1d (NS) 0.32 (0.05–2.01)
Allele
A 20 (18) 1 (2) 19 (43) 36 (12) 26 (10) 10 (33) 0.1 1.63 (0.86–3.08) 0.02 (NS) 0.14 (0.01–1.03) 0.3 1.52 (0.52–4.47)
G 90 (82) 65 (98) 25 (57) 264 (88) 244 (90) 20 (67)
30-UTR
Genotype
del/del 22 (40) 12 (36) 10 (46) 68 (46) 63 (47) 5 (34) 0.4 (NS) 0.8 (0.41–1.58) 0.2 (NS) 0.65 (0.28–1.53 0.46 (NS) 1.67 (0.35–8.14)
TGTG+/del 21 (38) 15 (46) 6 (27) 62 (41) 54 (40) 8 (53) 0.6 (NS) 0.88 (0.44–1.73) 0.56 (NS) 1.25 (0.54–2.87) 0.1 (NS) 0.33 (0.06–1.59)
TGTG+/+ 12 (22) 6 (18) 6 (27) 20 (13) 18 (13) 2 (13) 0.1 (NS) 1.81 (0.76–4.29) 0.31d (NS) 1.44 (0.46–4.35) 0.27d (NS) 2.44 (0.34–21.17)
Allele
del 65 (59) 39 (59) 26 (59) 198 (66) 180 (67) 18 (60) 0.1 0.74 (0.46–1.2) 0.24 0.72 (0.4–1.3) 0.93 0.96 (0.34–2.75)
TGTG+ 45 (41) 27 (41) 18 (41) 102 (34) 90 (33) 12 (40)
EPTB, extrapulmonary tuberculosis; M, male; F, female; OR, odds ratio; CI, conﬁdence interval; NS, not signiﬁcant; ND, not determined; pc, Bonferroni correction (as multiple comparisons were made, Bonferroni’s correction was
applied to a signiﬁcant p-value that was multiplied by the number of genotypes (three)).
a Male and female cases of extrapulmonary tuberculosis vs. male and female control cases.
b Male cases of extrapulmonary tuberculosis vs. male control cases.
c Female cases of extrapulmonary tuberculosis vs. female control cases.
d Fisher’s exact test.
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Table 4
D543N and 30-UTR allele and genotype frequencies (n (%)) in pulmonary tuberculosis cases and in controls by age group
29 years p-Valuea (pc) ORa (95% CI) 30–49 years p-Valueb (pc) ORb (95% CI) 50 years p-Valuec (pc) ORc (95% CI)
PTB (%) Controls (%) PTB (%) Controls (%) PTB (%) Controls (%)
D543N
Genotype
AA 10 (12) 1 (1) 6.103 (18.103) 10.8 (1.37–230.8) 0 (0) 0 (0) ND ND 0 (0) 0 (0) ND ND
AG 15 (18) 17 (21) 0.6 (NS) 0.82 (0.35–1.89) 25 (43) 10 (22) 0.02 (NS) 2.65 (1.02–7) 10 (40) 7 (30) 0.4 (NS) 1.52 (0.39–5.98)
GG 60 (70) 64 (78) 0.2 (NS) 0.68 (0.32–1.44) 33 (57) 35 (78) 0.02 (NS) 0.38 (0.14–0.98) 15 (60) 16 (70) 0.4 (NS) 0.66 (0.17–2.54)
30-UTR
Genotype
del/del 30 (68) 20 (36) 103 (3.103) 3.75 (1.5–9.52) 20 (40) 30 (57) 0.09 (NS) 0.51 (0.22–1.2) 30 (41) 18 (43) 0.8 (NS) 0.91 (0.39–2.1)
TGTG+/del 7 (16) 25 (46) 103 (3.103) 0.23 (0.08–0.65) 20 (40) 15 (28) 0.21 (NS) 1.69 (0.69–4.18) 40 (54) 22 (52) 0.8 (NS) 1.07 (0.47–2.45)
TGTG+/+ 7 (16) 10 (18) 0.7 (NS) 0.85 (0.26–2.74) 10 (20) 8 (15) 0.86 (NS) 1.09 (0.35–3.47) 4 (5) 2 (5) 0.6d (NS) 1.14 (0.17–9.46)
PTB, pulmonary tuberculosis; OR, odds ratio; CI, conﬁdence interval; NS, not signiﬁcant; ND, not determined; pc, Bonferroni correction (as multiple comparisons were made, Bonferroni’s correction was applied to a signiﬁcant p-
value that was multiplied by the number of genotypes (three)).
a Cases of pulmonary tuberculosis vs. control cases aged 29 years.
b Cases of pulmonary tuberculosis vs. control cases aged 30–49 years.
c Cases of pulmonary tuberculosis vs. control cases aged 50 years.
d Fisher’s exact test.
Table 5
D543N and 30-UTR allele and genotype frequencies (n (%)) in extrapulmonary tuberculosis cases and in controls by age group
29 years p-Valuea (pc) ORa (95% CI) 30–49 years p-Valueb (pc) ORb (95% CI) 50 years p-Valuec (pc) ORc (95% CI)
EPTB (%) Controls (%) EPTB (%) Controls (%) EPTB (%) Controls (%)
D543N
Genotype
AA 0 (0) 1 (1) 0.7d (NS) 0 (0–48.69) 0 (0) 0 (0) ND ND 0 (0) 0 (0) ND ND
AG 16 (53) 17 (21) 8.104 (24.104) 4.37 (1.64–11.82) 3 (19) 10 (22) 0.5d (NS) 0.81 (0.15–3.98) 1 (11) 7 (30) 0.2d (NS) 0.29 (0.01–3.2)
GG 14 (47) 64 (78) 103 (3.103) 0.25 (0.09–0.65) 13 (81) 35 (78) 0.5d (NS) 1.24 (0.25–6.76) 8 (89) 16 (70) 0.2d (NS) 3.5 (0.31–89.3)
30-UTR
Genotype
del/del 7 (54) 20 (36) 0.2 (NS) 2.04 (0.52–8.16) 5 (28) 30 (57) 0.03 (NS) 0.29 (0.08–1.07) 10 (42) 18 (43) 0.9 (NS) 0.95 (0.31–2.96)
TGTG+/del 2 (15) 25 (45) 0.04 (NS) 0.22 (0.03–1.21) 7 (39) 15 (28) 0.4 (NS) 1.61 (0.46–5.67) 12 (50) 22 (52) 0.8 (NS) 0.91 (0.3–2.79)
TGTG+/+ 4 (31) 10 (19) 0.3 (NS) 2 (0.42–9.32) 6 (33) 8 (15) 0.09d (NS) 2.81 (0.69–11.44) 2 (8) 2 (5) 0.4d (NS) 1.82 (0.17–19.84)
EPTB, extrapulmonary tuberculosis; OR, odds ratio; CI, conﬁdence interval; NS, not signiﬁcant; ND, not determined; pc, Bonferroni correction (asmultiple comparisons weremade, Bonferroni’s correctionwas applied to a signiﬁcant
p-value that was multiplied by the number of genotypes (three)).
a Cases of extrapulmonary tuberculosis vs. control cases aged 29 years.
b Cases of extrapulmonary tuberculosis vs. control cases aged 30–49 years.
c Cases of extrapulmonary tuberculosis vs. control cases aged 50 years.
d Fisher’s exact test.
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genotypes by age group, we found that del/del genotype might be
associated with an increased risk of the development of the PTB
form in those under 30 years of age (OR 3.75, 95% CI 1.5–9.52;
pc = 0.003) (Table 4). TGTG+/del appeared to be associated with
increased resistance against the development of active PTB (OR
0.23, 95% CI 0.08–0.65; pc = 0.003) (Table 4).
3.4. NRAMP1 (D543N and 30-UTR) haplotype and diplotype
distributions
We found that the correlation (r2) between the two NRAMP1
polymorphisms was low and that D0 showed evidence of
signiﬁcant LD only in the PTB+EPTB (r2 = 0.05; D0 = 0.614), PTB
(r2 = 0.03; D0 = 0.56), and EPTB (r2 = 0.14; D0 = 1) groups, but not in
the control group (r2 = 0.03; D0 = 0.67).
When we analyzed the four possible haplotypes, only A-del
showed signiﬁcant differences between patients with PTB and
control subjects (Table 6). This haplotype was over-represented in
the PTB group and associated with susceptibility to the clinical
form of PTB (18% vs. 11%; OR 1.79, 95% CI 1.11–2.9; pc = 0.04)
(Table 6).
Only six of the nine possible diplotype combinations were
found in patients with PTB and control individuals, and only ﬁve in
the EPTB patients. The GG/deldel diplotype was signiﬁcantly more
frequent in control subjects in comparison to EPTB patients and
appeared to be associated with a decreased risk of the develop-
ment of this clinical form of TB (25% vs. 7%, OR 0.24, 95% CI 0.07–
0.75; pc = 0.03).
4. Discussion
Polymorphisms in the NRAMP1 gene have been found to be risk
factors for the development of TB among different ethnic adult
populations in a number of genetic studies.37,38 However, no
distinction was made between the different clinical forms of active
TB (PTB and EPTB) in the patients enrolled in these studies, or age–
sex-speciﬁc effects. Such a study design might miss or underesti-
mate genetic control mechanisms that differ in the development of
PTB or EPTB. In the present study, we focused our genetic analysis
on different clinical forms of active TB in relation to the age and sex
of the patients enrolled, for the ﬁrst time in Tunisia. We found
strong associations between the NRAMP1 30-UTR and D543N
polymorphisms and susceptibility to mycobacterial infection in
Tunisian populations grouped by age and sex. These results could
explain in part the role of NRAMP1 in susceptibility to TB disease
and provide a plausible explanation for NRAMP1 genetic heteroge-
neity in TB susceptibility.
There have been signiﬁcant advances in our understanding of
the fundamental principles governing bacterial–host interactions.
However, the clinical management of TB is very complicated
because of the non-homogeneous nature of the patients.1
Resistance to bacterial infection is a heritable trait that appears
to be controlled by multiple genes. The innate immune system is of
central importance to the early containment of infection. Hence,
genetic variations or mutations that disrupt innate immune
sensing of infectious organisms could explain the ability of the
immune system to respond to infection, the diversity of clinical
presentations of TB, the response to current medical treatment,
and the genetic predisposition to infection in each individual
patient. Several lines of evidence suggest that the NRAMP1 gene is
an important candidate factor for susceptibility to active TB. In the
mouse, it has been shown that the absence of mature Nramp1
protein is the result of a G169D polymorphism, which causes
increased susceptibility to several intracellular macrophage
pathogens, including BCG, Salmonella typhimurium, and Leishmania
W. Ben-Selma et al. / International Journal of Infectious Diseases 16 (2012) e543–e550 e549donovani.39 In phagocytosing macrophages, Nramp1 is rapidly
recruited to the membrane of late endosomal–phagosomal
vesicles.18,40 At the phagosome membrane, Nramp1 functions as
a divalent cation pump,18,41 and Nramp1-altered cation ﬂuxes are
thought to abrogate pathogen-induced blockage of phagosome
maturation.42–44 The mechanism of action of NRAMP1 in human
macrophages is not known, but is thought to follow similar
mechanisms.
A number of recent studies now provide evidence that NRAMP1
polymorphisms are involved in determining autoimmune and
infectious disease susceptibility, and immune responses to
mycobacterial products.45 To date, studies that have assessed
NRAMP1 polymorphisms and their association with the risk of
development of active TB in humans have yielded conﬂicting
results. The initial study reported by Bellamy et al. demonstrated
that NRAMP1 polymorphisms were signiﬁcantly associated with
susceptibility to TB among West Africans.24 However, other studies
involving patients living in Morocco, Japan, and Brazil, have
suggested that NRAMP1 polymorphisms are not a risk factor for
TB.25,46,47 This discrepant data may be attributed to a number of
variant factors, such as the genetic background and clinical status
of the TB patients.
In the present study, genotyping of the two SNPs of the NRAMP1
gene was done correctly using previously reported PCR-RFLP
protocols in TB patients divided into groups according to age and
sex and compared to a control group.30 We found that the D543N-
A allele was signiﬁcantly over-represented in the PTB group in
comparison to the control group. This ﬁnding suggests that the
D543N-A allele might be associated with an increased risk of the
development of active PTB. In addition, this result appears to argue
for the association of the D543N-AA genotype with susceptibility
to PTB in our setting (OR 9.43; pc = 0.03). However, our ﬁnding is in
disagreement with those of previous studies, which have reported
a positive association of heterozygote D543N-AG genotype with
susceptibility to PTB in Gambia24 and Peru.48 Moreover, in some
studies with large sample sizes, no association between D543N
polymorphisms and TB were found.25,46,47 A possible explanation
for the apparent inconsistency between these studies is that
ethnic-speciﬁc genetic variations could greatly inﬂuence host
immunity to TB, causing different TB susceptibility depending on
the ethnic population studied. Another possible explanation might
be the relatively small size of the studied populations.
After adjusting the frequency distribution of D543N genotypes
by sex, we observed a signiﬁcant increase in resistance to the
development of active PTB in females in relation to wild-type GG
(OR 0.1; pc = 0.03). Interestingly, only patients aged less than 30
years harboring AA and AG genotypes were at increased risk of
developing PTB (OR 10.8; pc = 0.018) and EPTB (OR 4.37;
pc = 0.0024), respectively. However, patients with GG genotype
appeared to be protected against the development of active EPTB
(OR 0.25; pc = 0.003). Hence, this ﬁnding could explain in part the
heterogeneity in results reported by several studies on the
associations of D543N polymorphism and the risk of developing
active TB. Other studies should investigate genetic associations of
D543N polymorphism in relation to the gender and age of TB
patients.
The 30-UTR del allele frequencies were similar in the different
patient TB groups in comparison to healthy controls and did not
show any signiﬁcant statistical differences. Moreover, there were
no statistically signiﬁcant differences in the frequency distribu-
tions of the different genotypes between PTB patients, EPTB
patients, and the control group. Our ﬁndings are in agreement with
recently published data.25,46,47 However, we found that after
stratiﬁcation of the different genotypes by age group, the del/del
genotype was over-represented in PTB patients aged less than 30
years in comparison to the control group (68% vs. 36%). Moreover,this genotype appeared to be associated with an increased risk of
the development of PTB in this age group (OR 3.75; pc = 0.003). In
contrast, TGTG+/del genotype might be associated with increased
resistance against PTB (OR 0.23; pc = 0.003). This ﬁnding argues for
the importance of stratifying TB patients by age to better
understand the possible association between this polymorphism
and resistance/susceptibility to active TB.
Interestingly, in our study NRAMP1 30-UTR and D543N
polymorphisms appeared to be associated with an increased
susceptibility or protection against the risk of developing active
PTB, particularly in males aged less than 30 years. This association
could be related to one or both of the following factors: (1) The
polygenic aspect of susceptibility to active TB;4 in fact, other
genetic polymorphisms affecting genes encoding for cytokines or
their receptors that play a pivotal role in immunity against M.
tuberculosis could be associated with an increased risk of the
development of active EPTB. (2) Associations between cytokines or
receptors that play a role in the immune response in TB and the risk
of development of this disease could be inﬂuenced by age and sex.
In this setting, we recently reported that the variant AA genotype of
+874 A/T affecting the IFN-g gene was associated with active PTB in
men (OR 2.42) aged 30–49 years.9 However, patients aged more
than 50 years had a six-fold increased risk of developing active
EPTB. The A-del haplotype was signiﬁcantly more frequent in the
PTB group (pc = 0.04) in comparison to the control group.
Additionally, this haplotype appeared to be a risk factor for the
development of active PTB with a 1.79-fold increased risk. Finally,
of the nine possible diplotypes, only six were present in PTB
patients and in the control group, and only ﬁve were present in
EPTB patients. The GG/deldel diplotype was much more frequent in
controls (pc = 0.03) and might increase resistance against the
development of EPTB (OR 0.24).
We have reported here the ﬁrst study in the Tunisian
population showing how NRAMP1 genetic polymorphisms can
affect TB susceptibility in relation to age and sex. There were a
number of limitations to the current study. The ﬁrst is the lack of
matched age and gender distribution between the controls and
study subjects. A second is that the patients were from a single
geographic region, limiting the certainty that these data apply to
other regions. The third limitation is the size of the population,
which could also be expanded.
In summary, our data based on molecular genetics indicate that
30-UTR and D543N polymorphisms of the NRAMP1 gene are
associated with an increased susceptibility–resistance to different
clinical forms of active TB with sex- and age-speciﬁc effects in the
Tunisian population. Additional studies with TB patients from
diverse geographic and ethnic backgrounds will be required to
further investigate the relationships underlying these interesting
ﬁndings.
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